A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050 · Completed

Last updated 2026-05-28

This clinical trial tests the safety and effects of the drug MEDI0382 in adults who are overweight or obese and have type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 834 people

Who can join Ages 18–130 · all sexes

Timeline Started 2017-08 · est. completion 2019-06

Where 119 sites · Bulgaria, Canada, Czechia, Germany, Mexico, Russia, Slovakia, United States

What this study is testing ClinicalTrials.gov NCT03235050 ↗

Description as written by the study sponsor.

This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382

Treatments tested

MEDI0382 low dose Drug

Pharmaceutical form: solution Route of administration: subcutaneous
MEDI0382 mid dose Drug

Pharmaceutical form: solution Route of administration: subcutaneous
MEDI0382 high dose Drug

Pharmaceutical form: solution Route of administration: subcutaneous
Placebo Drug

Pharmaceutical form: solution Route of administration: subcutaneous
Liraglutide Drug

Pharmaceutical form: solution Route of administration: subcutaneous

Main thing measured	Change in HbA1c
Sponsor	AstraZeneca
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03235050 ↗